Search
for

    Research

    5 / 983 results

    Community Join

    5 / 1000+ results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 6 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community How much faith do you have in Kintor?

      in Research/Science  18 upvotes 4 years ago
      KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.

      community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China

      in Technology  13 upvotes 5 years ago
      The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

      community GT20029. Kintor Pharma’s Product

      in Research/Science  12 upvotes 3 years ago
      The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.